Last reviewed · How we verify
BIIB112
At a glance
| Generic name | BIIB112 |
|---|---|
| Also known as | AAV8-RPGR |
| Sponsor | Biogen |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Long-term Safety and Efficacy Follow-up of BIIB111 for the Treatment of Choroideremia and BIIB112 for the Treatment of X-Linked Retinitis Pigmentosa (PHASE3)
- A Clinical Trial of Retinal Gene Therapy for X-linked Retinitis Pigmentosa Using BIIB112 (PHASE1, PHASE2)
- Natural History of the Progression of X-Linked Retinitis Pigmentosa
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIIB112 CI brief — competitive landscape report
- BIIB112 updates RSS · CI watch RSS
- Biogen portfolio CI